Stable Pharma, a U.K. startup has developed technology that will stabilize heat-sensitive vaccines to protect against  SARS-CoV-2 for a two-month period without refrigeration.  Research conducted in cooperation with La Paz University Hospital in Madrid offers the potential to manufacture, transport and store mRNA vaccines without refrigeration with obvious implications for administration in remote nations with defeciencies in their cold chains.

If the technology could be applied to other live vaccines and cell-associated products, the World poultry industry would benefit especially with regard to both Marek's vaccines and Marek’s-based vectored products.